Innovative Research on Pap Test for Cancer Detection

Study Overview

A recent study conducted by a multi-national research team explored the potential of Pap test samples in diagnosing ovarian and endometrial cancer. The Pap test is a routine procedure performed in medical offices, where cervical cell samples are collected and analyzed. Abnormal results can lead to further testing and potential diagnosis of cervical cancer. This early detection capability allows for timely treatment, which significantly improves cancer survival rates and has contributed to a decrease in cervical cancer mortality.

Limitations of Current Testing Methods

Currently, there are no equivalent tests available for detecting endometrial or ovarian cancers with the same efficacy as the Pap test for cervical cancer. The ultrasound test is often used for detecting these types of cancers, but it struggles to differentiate between benign and malignant tumors. Alarmingly, only 2% of women who tested positive for endometrial cancer via ultrasound were confirmed to have the disease upon further investigation, leading to a high false-positive rate. Additionally, ultrasound is not effective in identifying early signs of ovarian cancer, resulting in poor survival rates for patients diagnosed at later stages.

Research Findings on Pap Test Utility

Utilizing Fallen Cancer Cells

Researchers from North America and Europe sought to improve early-stage diagnosis of endometrial and ovarian cancers, publishing their findings in *Science Translational Medicine*. Their approach leverages recent scientific insights, suggesting that cancer cells from endometrial and ovarian tumors can detach and be detected in cervical samples.

Methodology and Results

The study involved 656 patients diagnosed with endometrial or ovarian cancer via biopsy, alongside 1,002 cancer-free women. The testing revealed that 81% of women with endometrial cancer had identifiable mutations in their Pap test samples, while 29% of women with ovarian cancer showed similar results. The test demonstrated nearly 100% specificity for cancer detection among participants without cancer, contrasting sharply with the high false-positive rates associated with ultrasound testing.

The PapSEEK Test

Researchers identified some patients without detectable mutations in Pap test samples but with abnormal chromosomal numbers indicative of cancer. This led to the development of the “PapSEEK” test, which assesses both mutations and chromosomal abnormalities. Further investigations using samples collected directly from the uterus increased the detection rate of endometrial cancers from 81% to 93%, with 90% of early-stage cases identified. For ovarian cancer, detection rates improved from 29% to 45%.

Combining Testing Methods

Recognizing that tumor cells from ovarian cancer may not always reach the cervix, researchers also examined blood samples for circulating tumor DNA (ctDNA). Combining results from Pap tests and blood samples revealed a 63% detection rate for ovarian cancer, including 54% for early-stage cases.

Implications for Early Cancer Detection

The combined testing method developed by this research team could potentially identify early endometrial cancer in 90% of cases and early ovarian cancer in 54% of cases. These promising results indicate that such testing could facilitate earlier diagnoses when treatment is likely to be more effective. The authors suggest that further studies in clinical settings are essential to evaluate the feasibility of using this test as a routine surveillance tool, similar to the Pap test, for the general population.

Reference

Wang Y, Li L, Douville C, et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Sci Transl Med. 2018;10(433):eaap8793. doi:10.1126/scitranslmed.aap8793.